SG-210

• Description:

  SG-210 (SPR 210) is an orally active and selective aldose reductase (AR) inhibitor. SG-210 has IC50 values of 9.5 nM and 10 nM for AR from porcine lens and human placenta, respectively. SG-210 can inhibit sorbitol accumulation and ameliorate diabetic neuropathy and retinopathy in Streptozotocin (HY-13753) -induced diabetic rats. SG-210 can be used in the research of diseases such as diabetes-related complications[1].

• Product Name Alternative:

  SPR 210

• UNSPSC:

  12352005

• Target:

  Aldose Reductase

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease; Neurological Disease

• Smiles:

  O=C1N (CC2=NC3=C (S2) C (F) =CC (F) =C3F) C4=CC=CC=C4SC1CC (O) =O

• Molecular Formula:

  C18H11F3N2O3S2

• Molecular Weight:

  424.42

• References & Citations:

  [1]Matsui T, et al. Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats. Jpn J Pharmacol. 1994 Feb;64 (2) :115-24.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  143162-65-6